Embecta Corp. (Nasdaq: EMBC) has officially closed its acquisition of Owen Mumford Holdings Limited, a privately held UK-based medical device innovator. The deal marks a defining step in embecta’s evolution from a diabetes-focused company into a broad-based medical supplies powerhouse.
Deal Terms
First announced on March 19, 2026, the transaction involves an upfront cash payment of £100 million, with up to £50 million in additional performance-based payments tied to net sales of Owen Mumford’s flagship Aidaptus® next-generation auto-injector platform over the three years following closing.
A Strategic Leap Beyond Diabetes
The acquisition accelerates embecta’s transformation into a diversified medical supplies company, extending its reach well beyond its insulin delivery heritage. The company will now serve chronic care patients and pharmaceutical partners across four key therapeutic areas:
- Diabetes
- Obesity
- Autoimmune diseases
- Anaphylaxis
By combining Owen Mumford’s device design, molding, and assembly expertise with embecta’s global commercial infrastructure and large-scale manufacturing capabilities, the combined entity expects to unlock meaningful geographic expansion and operational efficiencies.
What Owen Mumford Brings to the Table
Founded in 1952 and headquartered in Oxfordshire, United Kingdom, Owen Mumford has spent over 70 years building a trusted reputation among pharmaceutical and biotech companies. The acquisition brings embecta:
- A differentiated drug-delivery platform designed to support partners across multiple therapeutic areas
- A robust intellectual property portfolio, anchored by the Aidaptus® auto-injector platform
- Strong device design, molding, and assembly capabilities for high-volume medical products
- A chronic care device portfolio spanning self-injection, diagnostics, and patient-focused point-of-care solutions
About embecta
Embecta is a global company advancing its 100-year legacy in insulin delivery toward becoming a broad-based medical supplies company. With approximately 2,500 employees worldwide, it develops innovative solutions that improve the lives of chronic care patients. Learn more at embecta.com.
About Owen Mumford
Owen Mumford is a medical technology company with over seven decades of innovation in healthcare device development. A long-standing partner to the pharmaceutical and biotech industries, the company develops drug delivery technologies for complex therapies and distributes patient-focused medical devices in markets around the world.